Article
Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Pharmacotherapy - 1 Dec 2013
Williams Casey B, Kambhampati Suman, Fiskus Warren, Wick Jo, Dutreix Catherine, Ganguly Siddartha, Aljitawi Omar, Reyes Ruben, Fleming Allan, Abhyankar Sunil, Bhalla Kapil N, McGuirk Joseph P
Abstract excerpt
PURPOSE: To determine the preclinical activity, clinical maximum tolerated dose (MTD), and recommended phase II dose of midostaurin (MS) combined either sequentially or concurrently with intravenous decitabine (DAC) in newly diagnosed patients 60 years or older or relapsed/refractory adult patients (18 years or older) with acute myeloid leukemia (AML). PATIENTS AND METHODS: Cultured and primary AML cells were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.